Opinion|Videos|January 20, 2025
Future Considerations for Front-line Treatment of DLBCL
An overview of key studies and updates from ASH 2024 offering new insights into subsequent treatment strategies and safety management in the first-line setting for DLBCL.
Advertisement
Video content above is prompted by the following:
- What studies or updates from ASH 2024 give new insights to subsequent treatment and safety management in the 1L setting.
Advertisement
Related to this article
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
Lisa Niswander, MD, PhD, of Roswell Park, is investigating ways to combine CAR T cells and a new class of targeted cancer drugs for younger leukemia.
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
UGN-103, a next-generation mitomycin formulation built on the ZUSDURI foundation, is supported by three-month CR and six-month DOR data from the phase 3 UTOPIA trial.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
No efficacy benefit was found in adding SBRT to dual checkpoint blockade, though a subset of patients responded to nivolumab plus ipilimumab.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Novel Approaches for Hematocrit Control Are Driving Research in Polycythemia Vera
2
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
3
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
4
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
5